Civica plans to produce insulin biosimilars in both vials and prefilled pens and sell them at significantly lower prices than insulins currently on the market, according to a Jan. 31 company press release.
The company plans to set the maximum recommended price to the consumer at $30 per vial and $55 per box of five pen cartridges. Civica products are anticipated to hit the market in 2024 after FDA approval.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.